Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1649989/000157104917005026/t1701473_10q.htm
SEC Filings
ONS Annual Reports
ONS Quarterly Reports
ONS Corporate News
Financial Exhibit
New Agreement
New Financial Obligation
Other Events
Security Holders Change
Unregistered Sales November 2018
Listing Status October 2018
Event for Officers
Financial Exhibit October 2018
Event for Officers
Financial Exhibit
Vote of Security Holders September 2018
Ending Agreement September 2018
Earnings Release
Financial Exhibit August 2018
Event for Officers
Financial Exhibit
Other Events August 2018
Bylaw Change
Financial Exhibit
New Agreement
Other Events
Security Holders Change
Unregistered Sales
Vote of Security Holders July 2018
Financial Exhibit
Other Events July 2018
Event for Officers July 2018
Financial Exhibit
New Agreement
New Financial Obligation
Other Events
Security Holders Change
Unregistered Sales
New Agreement
New Financial Obligation
Other Events
Security Holders Change
Unregistered Sales
November 2018
Listing Status
October 2018
Event for Officers
Financial Exhibit
Financial Exhibit
October 2018
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
September 2018
Ending Agreement
September 2018
Earnings Release
Financial Exhibit
Financial Exhibit
August 2018
Event for Officers
Financial Exhibit
Other Events
Financial Exhibit
Other Events
August 2018
Bylaw Change
Financial Exhibit
New Agreement
Other Events
Security Holders Change
Unregistered Sales
Vote of Security Holders
Financial Exhibit
New Agreement
Other Events
Security Holders Change
Unregistered Sales
Vote of Security Holders
July 2018
Financial Exhibit
Other Events
Other Events
July 2018
Event for Officers
July 2018
Last10K.com | 10-Q Quarterly Report Mon May 15 2017
Document And Entity Information - shares | 6 Months Ended | |
|---|---|---|
Mar. 31, 2017 | May 11, 2017 | |
| Document And Entity Information [Abstract] | ||
| Entity Registrant Name | Oncobiologics, Inc. | |
| Entity Central Index Key | 0001649989 | |
| Trading Symbol | ons | |
| Current Fiscal Year End Date | --09-30 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Common Stock, Shares Outstanding | 24,453,013 | |
| Document Type | 10-Q | |
| Document Period End Date | Mar. 31, 2017 | |
| Amendment Flag | false | |
| Document Fiscal Year Focus | 2017 | |
| Document Fiscal Period Focus | Q2 |
View differences made from one quarter to another to evaluate Oncobiologics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Oncobiologics, Inc..
Assess how Oncobiologics, Inc.'s management team is paid from their Annual Proxy
Oncobiologics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Expense Highlight
We anticipate that our general and administrative expenses will increase as a result of increased payroll, expanded infrastructure and an increase in accounting, consulting, legal and tax-related services associated with maintaining compliance with stock exchange listing and SEC requirements, investor relations costs, and director and officer insurance premiums associated with being a public company.
-
Financial - Expense Highlight
We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including stock-based compensation, conduct clinical trials and prepare regulatory filings for our biosimilar product candidates.
-
Revenue - Product Highlight
The change in our operating assets and liabilities was primarily due to increases in accounts payable related to the timing of vendor payments for research and development and in deferred revenues due to ratable recognition of upfront payments received under our collaboration arrangements.
-
Financial - Expense Highlight
Other general and administrative expenses include facility related costs, patent filing and prosecution costs and professional fees for business development, legal, auditing and tax services and insurance costs.
-
Financial - Expense Highlight
Interest expense increased by $0.6 million for the three months ended March 31, 2017 as compared to the three months ended March 31, 2016 primarily due to the amortization of debt discount and accrued interest on the senior secured notes issued in December 2016 and January 2017.
-
Financial - Expense
Interest expense increased by $0.6...Read more
-
Financial - Cash Flow
We have incurred operating losses...Read more
-
Other - Other
For example, if the U.S....Read more
-
Financial - Income
There is also a risk...Read more
-
Financial - Expense
General and administrative expenses for...Read more
-
Revenue - Product
Through March 31, 2017, we...Read more
-
Other - Other
We determined that there are...Read more
-
Financial - Expense
We also anticipate that our...Read more
-
Revenue - Product
Through March 31, 2017, we...Read more
-
Revenue - Product
The following table sets forth...Read more
-
Revenue - Product
We determined that the upfront...Read more
-
Financial - Expense
General and administrative expenses for...Read more
-
Other - Other
These inflows were partially offset...Read more
-
Revenue - Product
In conjunction with the strategic...Read more
-
Financial - Cash Flow
Since inception, we have incurred...Read more
-
Financial - Expense
Research and development expenses for...Read more
-
Financial - Expense
Research and development expenses for...Read more
-
Other - Other
In January 2014, we entered...Read more
-
Financial - Shares
We plan to finance our...Read more
-
Financial - Cash Flow
As described in their audit...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Consolidated Balance Sheets (unaudited)
Consolidated Balance Sheets (unaudited) (parentheticals)
Consolidated Statement Of Stockholders' Equity (deficit) (unaudited)
Consolidated Statements Of Cash Flows (unaudited)
Consolidated Statements Of Operations (unaudited)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (detail Textuals)
Basis Of Presentation And Summary Of Significant Accounting Policies (details 1)
Basis Of Presentation And Summary Of Significant Accounting Policies (details)
Basis Of Presentation And Summary Of Significant Accounting Policies (policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (tables)
Fair Value Measurements
Fair Value Measurements (details 1)
Fair Value Measurements (details 2)
Fair Value Measurements (details)
Fair Value Measurements (tables)
Liquidity
Liquidity (detail Textuals)
Organization And Description Of Business
Organization And Description Of Business (detail Textuals)
Property And Equipment
Property And Equipment (detail Textuals)
Property And Equipment (details)
Property And Equipment (tables)
Senior Secured Notes
Senior Secured Notes (detail Textuals)
Senior Secured Notes (details)
Senior Secured Notes (tables)
Stock Based Compensation (detail Textuals 1)
Stock Based Compensation (detail Textuals 2)
Stock Based Compensation (detail Textuals 3)
Stock Based Compensation (detail Textuals)
Stock Based Compensation (details 1)
Stock Based Compensation (details 2)
Stock Based Compensation (details 3)
Stock Based Compensation (details)
Stock-based Compensation
Stock-based Compensation (tables)
Stockholders' Equity (deficit)
Stockholders' Equity (deficit) (detail Textuals 1)
Stockholders' Equity (deficit) (detail Textuals)
Stockholders' Equity (deficit) (details)
Stockholders' Equity (deficit) (tables)
Material Contracts, Statements, Certifications & more
Oncobiologics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ONS
CIK: 1649989
Form Type: 10-Q Quarterly Report
Accession Number: 0001571049-17-005026
Submitted to the SEC: Mon May 15 2017 5:05:38 PM EST
Accepted by the SEC: Mon May 15 2017
Period: Friday, March 31, 2017
Industry: Biological Products No Disgnostic Substances
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/ons/0001571049-17-005026.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...